Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients

Tacrolimus is the cornerstone in pediatric liver transplant immunosuppression. Despite close monitoring, fluctuations in tacrolimus blood levels affect safety and efficacy of immunosuppressive treatments. Identifying the factors related to the variability in tacrolimus exposure may be helpful in tailoring the dose. The aim of the present study was to characterize the clinical, pharmacological, and genetic variables associated with systemic tacrolimus exposure in pediatric liver transplant patients. De novo transplant patients with a survival of more than 1 month were considered for inclusion and were genotyped for cytochrome P450 3A5 (CYP3A5). Peritransplant clinical factors and laboratory covariates were recorded retrospectively between 1 month and 2 years after transplant, including alanine aminotransferase (ALT), aspartate aminotransferase, hematocrit, and tacrolimus predose steady‐state blood concentrations collected 12 hours after tacrolimus dosing. A linear mixed effect (LME) model was used to assess the association of these factors and the log‐transformed tacrolimus dose‐normalized trough concentration (logC0/D) levels. Bootstrapping was used to internally validate the final model. External validation was performed in an independent group of patients who matched the original population. The developed LME model described that logC0/D increases with increases in time after transplant (β = 0.019, 95% confidence interval [CI], 0.010‐0.028) and ALT values (β = 0.00030, 95% CI, 0.00002‐0.00056), whereas logC0/D is significantly lower in graft CYP3A5 expressers compared with nonexpressers (β = −0.349, 95% CI, −0.631 to −0.062). In conclusion, donor CYP3A5 genotype, time after transplant, and ALT values are associated with tacrolimus disposition between 1 month and 2 years after transplant. A better understanding of tacrolimus exposure is essential to minimize the occurrence of an out‐of‐range therapeutic window that may lead to adverse drug reactions or acute rejection.

[1]  J. Klawitter,et al.  Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  D. Mager,et al.  Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? , 2018, Journal of clinical pharmacology.

[3]  M. Lafreniere-Roula,et al.  A randomized clinical trial of age and genotype‐guided tacrolimus dosing after pediatric solid organ transplantation , 2018, Pediatric transplantation.

[4]  Dan S. Borgnia,et al.  Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation , 2018, Therapeutic drug monitoring.

[5]  C. Ensor,et al.  Increasing tacrolimus time‐in‐therapeutic range is associated with superior one‐year outcomes in lung transplant recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Åsberg,et al.  Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose , 2018, Pharmacological research.

[7]  D. Hesselink,et al.  A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation , 2017, Clinical Pharmacokinetics.

[8]  P. Schaiquevich,et al.  Pharmacoepidemiology of tacrolimus in pediatric liver transplantation , 2017, Pediatric transplantation.

[9]  A. Amoroso,et al.  Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation , 2017, British journal of clinical pharmacology.

[10]  D. Sautereau,et al.  Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients , 2016, Transplantation.

[11]  J. Otte Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  L. Weber,et al.  Therapeutic monitoring of immunosuppressive drugs in pediatric patients: special considerations , 2016, Expert review of clinical pharmacology.

[13]  C. Staatz,et al.  Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients , 2016, Antimicrobial Agents and Chemotherapy.

[14]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing , 2015, Clinical pharmacology and therapeutics.

[15]  Y. Zhang,et al.  Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. , 2015, International journal of clinical pharmacology and therapeutics.

[16]  Jian-jun Zhang,et al.  Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation , 2014, PloS one.

[17]  C. Staatz,et al.  Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients: A Meta-Analysis , 2014, Therapeutic drug monitoring.

[18]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[19]  J. McElnay,et al.  Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients , 2014, British journal of clinical pharmacology.

[20]  P. Wallemacq,et al.  Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver Transplantation , 2013, Therapeutic drug monitoring.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  D. Hesselink,et al.  The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.

[23]  Bodo Winter,et al.  Linear models and linear mixed effects models in R with linguistic applications , 2013, ArXiv.

[24]  C. Verstuyft,et al.  Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism. , 2013, Pharmacogenomics.

[25]  P. Marquet,et al.  Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure , 2013, Therapeutic drug monitoring.

[26]  P. Wallemacq,et al.  Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation , 2013, European Journal of Clinical Pharmacology.

[27]  M. Karlsson,et al.  Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance , 2011, Therapeutic drug monitoring.

[28]  G. Koren,et al.  The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation , 2011, European Journal of Clinical Pharmacology.

[29]  B. McCrindle,et al.  Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children , 2010, Pediatric transplantation.

[30]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[31]  D. Kelly,et al.  Calcineurin inhibitor minimization in pediatric liver allograft recipients , 2009, Pediatric transplantation.

[32]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[33]  B. Charpentier,et al.  Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.

[34]  S. Uemoto,et al.  Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living‐donor liver transplant recipients , 2006, Clinical pharmacology and therapeutics.

[35]  D. Kelly Current issues in pediatric transplantation , 2006, Pediatric transplantation.

[36]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[37]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[38]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[39]  C. Staatz,et al.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients , 2002, Clinical pharmacology and therapeutics.

[40]  M. Stoll,et al.  Pediatric , 1997, Bone Marrow Transplantation.

[41]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[42]  C. Manzanares,et al.  Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy , 2001, Clinical Pharmacokinetics.

[43]  S. Chan,et al.  Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. , 2000, British journal of clinical pharmacology.

[44]  M. Brunet,et al.  Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[45]  J. Hooff,et al.  Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. , 1998, Transplantation proceedings.

[46]  S. Todo,et al.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. , 1991, Transplantation proceedings.